Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. - Wikidata - wikimedia - TriplyDB

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

http://www.wikidata.org/entity/Q37623007

about

Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma.Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan.Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.Targeted therapies in brain metastases.Sunitinib toxicity management - a practical approach.Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.Sorafenib for the management of advanced renal cell carcinoma.Sorafenib for the treatment of renal cancer.Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.Treatment selection in metastatic renal cell carcinoma: expert consensus.Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature.Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma.Immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. Is there a rational for anti-angiogenic therapy?Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study.Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data.Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients.

P2860

Q30671049-15A77E4A-C060-4CF1-81AC-A91913269AFD Q30842235-EBFAA375-6768-456E-AC49-8CC83218E76E Q33419600-F44A6961-E5D5-4EB0-9588-5727B628A035 Q33668241-1DB3DA55-E244-4AD2-A49B-E2439B85AD71 Q33702779-12BB8E19-6CB3-4782-963E-C1F1D8AA0156 Q34657590-79CBCFE0-84FE-4236-9AAF-20F684ED8EA2 Q34660431-FFDF4DF4-F7A1-4FF2-8676-892454E6916E Q34982554-BA3E023A-7E11-447B-A75A-5F775D51772F Q35677270-095D53F0-8C0F-40D8-9E70-3E15979591B5 Q35753647-CCEB863B-8A29-4484-B5CF-E25A11649255 Q35865726-E943F042-61B8-45C3-B74F-3CD11651066A Q35927136-A9704BDA-F958-4DCD-A7C8-006E5039272E Q35932363-EE9CAD32-E90D-4000-AF9C-207B436B2DC1 Q37491460-31FBEF75-4B59-44C9-820A-FB766480C62C Q37560644-2AF04D0D-19AF-4439-BCE0-14FFA2069099 Q37863524-BA749420-EA3B-4C12-947C-1D2651A76BD3 Q37894667-7E2A7A1A-C658-4593-80EF-4EAEBA1F8A3A Q37977494-92F7704F-5CF1-44E3-9FEA-96CE20E96FFB Q37996240-C77A7BA5-811A-4956-B095-1F72D81037B9 Q37999655-A8120C3C-9E73-4296-8D71-77AE71F5F5A7 Q38091137-DA0EA9A2-E2E9-4FC7-8BE3-7DE1B2ED0845 Q38293247-31E1647E-56B4-4E52-BB1F-90021D479BBD Q38633488-B167CF40-5607-405A-8588-72911B188EB1 Q38658255-421E1EAB-095E-4694-80F6-E027DD59DF02 Q38907399-AB07E824-0CEF-43EE-B7BA-8479397F07E7 Q39356281-3DA9D5C8-6F30-4534-AD7B-81E10E73D068 Q42734821-73BC8A40-83B4-42BE-BCF7-AA35DF84535E Q43566220-8622575C-7B2D-4417-968C-6B955BD51DE1 Q48592854-F695B59A-257E-44A9-A9BF-572B6257147B Q50300725-34DC38F6-423C-44FB-B8F3-19E5E45FF22E Q53630353-58322AE7-BF6E-45CD-AE87-3E262474EF07

P2860

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

http://www.wikidata.org/entity/Q37623007

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiogenesis inhibitor therapi ...... based on medical chart review.

@en

Angiogenesis inhibitor therapi ...... based on medical chart review.

@nl

type

label

Angiogenesis inhibitor therapi ...... based on medical chart review.

@en

Angiogenesis inhibitor therapi ...... based on medical chart review.

@nl

prefLabel

Angiogenesis inhibitor therapi ...... based on medical chart review.

@en

Angiogenesis inhibitor therapi ...... based on medical chart review.

@nl

P1433

Q37623007-F6D29DFC-CB0F-4E75-80A0-FF89EC2A9666

P1476

Q37623007-12ACDE5D-D70D-453C-880D-D0DC418E1F5E

P2093

Q37623007-011C2B54-8EF8-4792-921F-F623058C187D

Q37623007-0C3C1284-1916-4322-9B0D-1520202506E8

Q37623007-0ED0B9ED-C3FA-4108-98FC-D3542007986D

Q37623007-0F2290E8-33E7-4FC4-A44C-872780BDACAE

Q37623007-35BB3705-A3EA-4C04-8B8C-6BA97D746472

Q37623007-412F8E3B-814C-4943-B195-EFBA1976FD68

Q37623007-45A58F06-BEFF-4924-8F11-23F493F50722

Q37623007-4D6E4641-D7F4-44EA-81E3-A6B31F5BD7CA

Q37623007-4EB98E87-F5AE-49C0-B154-DB0AE9E44A36

Q37623007-8F8FAD9B-D58B-415F-87B1-3C8B4283D743

P304

Q37623007-2A501F8A-AA38-4073-BE1B-096D65E4B049

P31

Q37623007-0B5C7404-619D-4ECB-9B17-6C62A3372D0F

P356

Q37623007-F5414240-594C-4438-A98C-328EB8C0441B

P433

Q37623007-C212E861-2073-44EC-946C-6468433ABD96

P478

Q37623007-93084874-8137-42D4-9C68-6B87DF646C99

P50

Q37623007-DC88A5CA-24DC-4841-A97E-A7D4B82509B6

P577

Q37623007-A11D58A3-4D99-43D3-83C2-C875C39EA9AF

P698

Q37623007-F0431F4E-FDC8-4649-9279-81EC69B9BBCA

P356

J.1464-410X.2009.08972.X

P1433

BJU International

P1476

Angiogenesis inhibitor therapi ...... -based on medical chart review

@en

P2093

Andi Luka

http://www.w3.org/2001/XMLSchema#string

Andrew G Percy

http://www.w3.org/2001/XMLSchema#string

Ashley J Brick

http://www.w3.org/2001/XMLSchema#string

Christabel Kwabi

http://www.w3.org/2001/XMLSchema#string

David McDermott

http://www.w3.org/2001/XMLSchema#string

Jessica Clement

http://www.w3.org/2001/XMLSchema#string

Karishma Shah

http://www.w3.org/2001/XMLSchema#string

Kristina Chen

http://www.w3.org/2001/XMLSchema#string

Lucia Antràs

http://www.w3.org/2001/XMLSchema#string

Maureen P Neary

http://www.w3.org/2001/XMLSchema#string

P304

1247-1254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2009.08972.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19863525

http://www.w3.org/2001/XMLSchema#string